EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Status:
Recruiting
Trial end date:
2024-02-07
Target enrollment:
Participant gender:
Summary
Primary Objective
-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and
improving sense of smell
Secondary Objectives
- To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared
to omalizumab
- To evaluate the efficacy of dupilumab in improving lung function at Week 24 compared to
omalizumab
- To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at
Week 24 compared to omalizumab
- To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24
compared to omalizumab
- To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week
24 compared to omalizumab
- To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24
compared to omalizumab
- To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab
- To evaluate the safety of dupilumab and omalizumab